Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Trial of Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

NCT06908993 is registered in ClinicalTrials.gov with Intergroupe Francophone de Cancerologie Thoracique as lead sponsor.

NCT NCT06908993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06908993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Trial of Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer
Lead sponsor
Intergroupe Francophone de Cancerologie Thoracique
Phase
Phase 3
Overall status
Recruiting
Start date
December 9, 2025
Completion date
July 15, 2028
Enrollment
133 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non small cell lung cancer, met exon 14 mutation